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Molecular subtypes of breast cancer: long-term incidence trends and prognostic 
differences. 
 
Background: Secular trends in incidence and prognosis of molecular breast cancer subtypes 
are poorly described. We studied long-term trends in a population of Norwegian women born 
1886-1977.  
Methods: A total of 52 949 women were followed for breast cancer incidence, and 
1423 tumours were reclassified into molecular subtypes using immunohistochemistry and in 
situ hybridization. We compared incidence rates among women born 1886-1928 and 1929-
1977, estimated age-specific incidence rate ratios (IRRs), and performed multiple imputations 
to account for unknown subtype. Prognosis was compared for women diagnosed before 1995 
and in 1995 or later, estimating cumulative risk of death and hazard ratios (HR).  
Results: Between 50-69 years of age, incidence rates of Luminal A and Luminal B 
(Human epidermal growth factor receptor (HER2)-) were higher among women born in 1929 
or later, compared to before 1929 (IRRs 50-54 years, after imputations: 3.5, 95% confidence 
interval (CI) 1.8-6.9 and 2.5, 95% CI 1.2-5.2, respectively), with no clear differences for other 
subtypes. Rates of death were lower in women diagnosed in 1995 or later, compared to before 
1995, for Luminal A (HR 0.4, 95% CI 0.3-0.5), Luminal B (HER2-) (HR 0.5, 95% CI 0.3-
0.7), and Basal phenotype (HR 0.4, 95% CI 0.2-0.9). 
Conclusion: We found a strong secular incidence increase restricted to Luminal A and 
Luminal B (HER2-) subtypes, combined with a markedly improved prognosis for these 
subtypes and for the Basal phenotype. 
Impact: This study documents a clear secular increase in incidence and a concomitant 








Breast cancer incidence rates have gradually increased in Norway since the 1950s (1, 2), with 
a markedly stronger increase starting in the early 1990s. Breast cancer mortality remained 
stable from the 1950s until around 1995, since then there has been a clear and consistent 
decline (1). Similar changes in incidence and mortality have been observed in most developed 
countries (3-6). However, long-term secular trends in incidence and prognosis of molecular 
subtypes of breast cancer are poorly documented. 
The heterogeneous nature of breast cancer that is observed both clinically and 
histopathologically, is also apparent in gene expression patterns (7, 8). Using 
immunohistochemistry (IHC) and in situ hybridization (ISH) as surrogates for gene 
expression analysis, archival tumour tissue can be reclassified into molecular subtypes (7-12). 
We used IHC and ISH to reclassify incident tumours into six subtypes: Luminal A [oestrogen 
receptor (ER) and/or progesterone receptor (PR)+, human epidermal growth factor receptor 2 
(HER2)-, Ki67<15%], Luminal B (HER2-) [ER and/or PR+, HER2-, Ki67≥15%], Luminal B 
(HER2+) [ER and/or PR+, HER2+], HER2 type [ER-, PR-, HER2+], 5 negative phenotype 
[ER-, PR-, HER2-, Cytokeratin 5 (CK5)-, and epidermal growth factor receptor (EGFR)-], 
and Basal phenotype [ER-, PR-, HER2-, CK5+ and/or EGFR+].   
Our main aim was to study long-term trends in incidence of different molecular breast 
cancer subtypes in a population of Norwegian women born between 1886 and 1977. Our 
second aim was to study the prognosis of molecular breast cancer subtypes diagnosed among 




Materials and methods  
This follow-up study comprises women from two population-based surveys conducted in 
Nord-Trøndelag County, Norway. Information on incident breast cancer was obtained from 
the Cancer Registry of Norway, date of death and/or emigration from Statistics Norway, and 
causes of death from the Norwegian Cause of Death Registry. Pathology reports and 
formalin-fixed, paraffin-embedded (FFPE) tissue from the first primary tumour were retrieved 
from the Department of Pathology and Medical Genetics at St. Olav’s Hospital, Trondheim 
University Hospital, Norway.  
Cohort 1. The first survey was conducted between 1956 and 1959, as part of a larger 
study that also included two other counties (13). We studied women from Nord-Trøndelag 
County, comprising a total of 25 727 women born between 1886 and 1928 who were 
followed for breast cancer occurrence from January 1st, 1961 until December 31st, 2008. 
Follow-up was facilitated by the introduction of the unique 11-digit identity number of all 
Norwegian citizens in 1961. In total, 1379 incident cases were diagnosed during follow-up, 
and 909 of these tumours were previously subtyped by our group (11). Some tumours were 
diagnosed at other hospitals, in particular in the 1960s and 1970s, and tumour tissue from 
these cases was not available for this study. After diagnosis, all patients were followed until 
death from breast cancer or death from other causes, or until December 31st, 2010.  
  Cohort 2. The second survey was conducted between 1995 and 1997. In this study, all 
women in Nord-Trøndelag County aged 20 years or older were invited to participate in the 
second wave of the HUNT Study in Nord-Trøndelag  (14). A total of 34 221 women born 
between 1897 and 1977 participated. From attendance until December 31st, 2009, 728 women 
were diagnosed with breast cancer. Of these, 157 were already included in Cohort 1. Of the 
remaining tumours, 57 were unavailable for subtyping, resulting in a total of 514 tumours 
from Cohort 2 that were subtyped in the present study (Figure 1). After diagnosis, these 
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patients were followed until death from breast cancer or death from other causes, or until 
December 31st, 2013.  
In the present study, we merged data from the two cohorts (Figure 1). In accordance 
with the requirements and conditions of the ethical approval of the study, patient identity was 
known to us for breast cancer cases but not for the underlying populations. Since there was 
some overlap in birth year between Cohort 1 and 2, we restricted Cohort 2 to women born 
after 1928 (n=27 222) to avoid duplicate observations in the incidence analyses. In the 
restricted cohort, there were 529 incident breast cancers, including 480 of the 514 cases that 
could be subtyped. In the analysis of incidence rates, we therefore used data from a total of 
1908 incident breast cancers that occurred among 52 949 women; 1379 (909 subtyped cases) 
from Cohort 1, and 529 (480 subtyped cases) from Cohort 2.  
In the analyses of prognosis for different breast cancer subtypes, we included all 514 
cases from Cohort 2 and the 909 cases from Cohort 1, yielding a total of 1423 subtyped cases.  
 
Specimen characteristics 
 New 4-μm thick sections from representative paraffin blocks were stained with 
haematoxylin–erythrosine–saffron (HES), reviewed by two pathologists independently, and 
classified into histopathological type and grade (15, 16). Any discrepancies were discussed, 
and consensus reached. Tumour size was measured on the glass slide, and correlated to 
information in the pathology report. In cases with multifocal tumours, the largest tumour was 
selected. 
Tissue microarrays (TMA) were constructed using the Tissue Arrayer MiniCore® 
3 with TMA Designer2 software (Alphelys, 78370 Plaisir, France). Three tissue cores (1-mm 
in diameter) from the tumour periphery were inserted into TMA recipient blocks, and 4-μm 
thick sections were cut and mounted on Superfrost+ glass slides, dried at 37°C overnight, and 
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stored in the freezer at -20°C. For IHC, slides were heated to 60°C for 2 hours, and pre-
treated in a PT Link, Pre-Treatment Module for Tissue Specimens (Dako Denmark A/S, 2600 
Glostrup, DK) with buffer (Low pH Target Retrieval Solution K8005 for Ki67, High pH 
Target Retrieval Solution K8004 for all other markers) at 97°C for 20 minutes.  
Slides were stained with HES, and immunostaining for ER (Clone SP1, concentration 
33 mg/mL, dilution 1:100, Cell Marque, Rocklin, United States), PR (Clone 16, concentration 
360 mg/L, dilution 1:400, NovoCastra Laboratories, Newcastle Upon Tyne, UK), HER2 
(Clone CB11, concentration 3.9 g/L, dilution 1:640, Novocastra), the proliferation marker 
Ki67 (Clone MIB1, concentration 35 mg/L, dilution 1:100, Dako Denmark A/S, Glostrup, 
Denmark), and basal markers CK5 (Clone XM26, concentration 50 mg/l, dilution 1:100, 
Novocastra) and EGFR (Clone 2-18C9, concentration ready to use, no dilution, Dako) was 
done in a DakoCytomationAutostainer Plus (Dako). Dako REAL™EnVision™ Detection 
System with Peroxidase/DAB+, Rabbit/Mouse, code K5007, was used for visualization for all 
markers except EGFR. EGFR was immunostained and visualized with EGFR pharmDXTM 
kit, code K1494 (Dako). Negative controls were included in all staining runs. 
Chromogenic ISH (Cohort 1) and fluorescence ISH (Cohort 2) were used to 
demonstrate the HER2 gene and chromosome 17 centromere. The dual-colour probe kit 
HER2 CISH pharmDxTM Kit, code 109 (Dako) was used for CISH (11), and HER2 IQFISH 
DAKO pharmDX Kit K 5731 (Dako) was used for FISH. Pre-treatment was done with pepsin 
solution at 37˚C for 25 minutes for both CISH and FISH.   
 
Scoring and reporting 
Slides were scanned using Ariol™ SL-50 3.3 Scan system (Genetix Europe Ltd., Gateshead, 
UK). IHC markers were assessed by two researchers independently. Discrepant results were 
discussed, and consensus reached.  
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HER2 status was assessed with a bright-field microscope (Nikon Eclipse 80i) (Cohort 
1) and a fluorescence microscope (Nikon Eclipse 90i) with Cytovision software version 3.7 
(Applied Imaging International Ltd., Newcastle-upon-Tyne, UK) (Cohort 2).  
 
Classification of markers 
ER and PR were positive when ≥1% of tumour nuclei showed positive staining, irrespective 
of staining intensity (17). Ki67 was counted in 500 tumour cells (hotspots), and considered 
high when ≥15% of nuclei were positive, irrespective of staining intensity (10, 18-20). 
Membranous staining for HER2 was scored from 0 to +3, (0/+1 negative; +2 
borderline/equivocal; +3 positive) (21). HER2 amplification was defined as a gene to 
chromosome ratio ≥2. At least 20 non-overlapping, well-preserved tumour cell nuclei with 
signals for both HER2 and chromosome 17 centromere were assessed. Tumours with 
unsuccessful ISH, but IHC +3, were considered positive.  
For CK5 and EGFR, a staining index was calculated by multiplying the proportion of 
positive staining cells (1 (<10 %); 2 (10-50 %); 3 (>50 %)) by staining pattern/intensity. 
Staining intensity for CK5 was defined as 0 (no staining); 1 (weak); 2 (moderate) and 3 
(strong). For EGFR, membranous staining was 0 (no staining); 1 (faint, incomplete staining); 
2 (moderate intensity, circumferential staining); 3 (strong intensity, circumferential staining), 
according to Dako PharmDX kit guidelines. A staining index of 0-1 was classified as 
negative, 2-9 as positive. The REMARK recommendations for reporting tumour marker 
studies were followed (22).  
 
Classification of tumours 
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Tumours were classified into the following six molecular subtypes: Luminal A, Luminal B 
(HER2-), Luminal B (HER2+), HER2 type, 5 negative phenotype and Basal phenotype, based 
on IHC and ISH results, as previously described (11). 
To allow comparison with previous studies (23-25), tumours were also classified into 
four subtypes according to hormone receptor- and HER2 status: ER+ and/or PR+, HER2-; 
ER+ and/or PR+, HER2+; ER- and PR-, HER2+, and ER- and PR-, HER2-. The results are 
presented as supplementary material.  
 
Statistical analyses 
During follow-up for breast cancer occurrence, censoring was done at time of death or 
emigration. Incidence rates were estimated separately for women born before 1929 and 
women born in 1929 or later. Age-specific rates were calculated to account for differences in 
age at baseline, and variations in age at diagnosis between subtypes. Estimates of incidence 
rates were plotted according to birth year and age for all incident cancers combined, and for 
each subtype separately. Poisson regression was used to compare incidence rates between 
women born before 1929 and women born in 1929 or later. The data allowed comparison of 
incidence rates in the age range 50-69 years. In the comparisons of Luminal A and Luminal B 
(HER2-), we had sufficient statistical power to use 5-year categories of age within that age-
range, estimated as incidence rate ratios (IRRs) with 95% confidence intervals (CI). For the 
remaining subtypes, statistical power was limited and we used 10-year categories in the 
incidence comparisons.  
For some cases, tumour tissue was unavailable, or the tumours could not be subtyped 
for other reasons. Thus, tumours from 34% of cases born before 1929, and 9% of cases born 
in 1929 or later could not be subtyped. Consequently, the observed subtype-specific incidence 
rates would underestimate the true rates, and underestimation would be greater for women 
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born before 1929, because their tumour subtype was more likely to be unknown. To 
compensate for this, we performed multiple imputations to predict the molecular subtype of 
these tumours (24, 26), assuming samples were missing at random (27). The imputation 
model included all information available: age (5-year categories) and calendar year at 
diagnosis (continuous), stage (I, II, III, IV, unknown) and extent of disease (disease localized 
to the breast, local invasion, regional lymph nodes, distant lymph nodes or organ metastases,  
unknown) as reported by the Cancer Registry of Norway, year of birth (5-year categories), 
observation time after diagnosis (log-transformed, continuous) and survival status (alive, 
death from breast cancer, death from other causes). Excluding each of the following variables 
in turn; stage, extent of disease or survival time, had no major influence on the imputed rates, 
nor did changing the categorization of continuous variables. Descriptive statistics for the 
information used in the imputation models are available in Supplementary Table 1. Incidence 
rates with 95% CIs were calculated based on 50 imputed data sets according to birth year and 
5-year age categories. 
In analyses of prognosis, we distinguished between women diagnosed before 1995 and 
women diagnosed in 1995 or later, to approximate the gradual implementation of  adjuvant 
treatment (including effective chemotherapy, anti-hormonal treatment and trastuzumab) in 
Norway (28). For each subtype, we calculated cumulative incidence of death from breast 
cancer at 5 and 15 years after diagnosis, treating deaths from other causes as competing 
events. Gray’s test was used to test equality between cumulative incidence curves.  
We used Cox proportional hazards models to compare the rate of death within each 
diagnostic period according to molecular subtype, and to compare the rate of death for each 
subtype between diagnostic periods. In the latter analysis, estimations were made for the first 
5 and 15 years after diagnosis, and for the entire follow-up period. We estimated hazard ratios 
(HRs) with 95% CIs from the month of diagnosis until death, with censoring at time of death 
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from other causes, and with adjustments for age, stage and histopathological grade at 
diagnosis. No clear violations of proportionality were found in log-minus-log plots. Stata 
version 13.1 (Stata Corp., College Station, TX, USA) was used for statistical analyses.  
 
Ethical approval 
The study was approved by the Regional Committee for Medical and Health Sciences 




Age-specific incidence rates according to year of birth 
Mean age at baseline was 51.0 years for women born before 1929, and 43.4 years for women 
born in 1929 or later. Mean follow-up times in the two groups of women were 29.7 and 13.1 
years, respectively.  
Between 50 and 69 years of age, total breast cancer incidence was higher for women 
born in 1929 or later, compared to women born before 1929 (Table 1, Supplementary Figure 
1). In subtype-specific analyses, incidence rates of Luminal A and Luminal B (HER2-) were 
consistently higher in women born in 1929 or later (Table 1, Figure 2). The higher incidence 
was particularly evident in the age group 50-54 years (IRR 7.7, 95% CI 3.4-17.4 and IRR 5.9, 
95% CI 2.4-14.5, respectively) and weaker in the 65-69 year age group (IRR 2.3, 95% CI 1.6-
3.5 for Luminal A and IRR 1.2, 95% CI 0.6-2.3 for Luminal B (HER2-)). Although the 
incidence rates for Luminal B (HER2+) and non-luminal subtypes were also higher for 
women born in 1929 or later, the differences were much less pronounced and varied 
considerably between age groups.  
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After imputation for unknown subtype, the observed relative rates (IRR) for Luminal 
A and Luminal B (HER-) were strongly attenuated (Table 1). Thus, the IRR for Luminal A 
breast cancer in the age group 50-54 years was reduced from 7.7 to 3.5 (95% CI 1.8-6.9), and 
for Luminal B (HER2-), there was a corresponding reduction in IRR from 5.9 to 2.5 (95% CI 
1.2-5.2) after imputation. The IRRs for Luminal B (HER2+) and the non-luminal subtypes 
were almost fully attenuated after imputation (Table 1). 
Incidence analysis based on observed data for the four subtypes determined by ER, 
PR, and HER2 status showed a marked incidence increase for the ER+, PR+, HER2- subtype, 
with an IRR of 6.9 (95% CI 3.8-12.6) for the age group 50-54 years. After imputation, the 
IRR was attenuated to 3.1 (95% CI 1.9-5.1). The results of these analyses are reported in 
detail in Supplementary Table 2 and Supplementary Figure 2.  
 
Prognosis according to molecular subtype and year of diagnosis 
Mean follow-up after diagnosis was 9.8 years for patients diagnosed before 1995, and 7.9 
years for patients diagnosed in 1995 or later. Women diagnosed in 1995 or later were on 
average younger, and their tumours were more often Luminal A and of lower grade. 
Furthermore, tumours diagnosed in 1995 or later were generally smaller compared to those 
diagnosed before 1995 (Table 2). However, information on tumour size was frequently 
missing or insufficiently described in the pathology reports from the first diagnostic period.  
In both diagnostic periods, Luminal A had the best prognosis, and HER2 type had the 
poorest (Table 3, Figure 3). Although the absolute risks of death for each subtype differed 
between diagnostic periods, the patterns of risk between subtypes remained roughly similar.  
The cumulative risk of death from Luminal A breast cancer was 37 % (95% CI 32-
44%) after 15 years of follow-up for women diagnosed before 1995 (Table 3, Figure 3), and 
13% (95% CI 9-17 %) in women diagnosed in 1995 or later, indicating a strong decline in 
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case fatality from the first to the second diagnostic period. The corresponding cumulative risk 
of death for women diagnosed with HER2 type was 57% (95% CI 44-71%) and 42% (95% CI 
28-60%). 
We used Cox regression analysis to compare rates of death between subtypes in each 
diagnostic period, and found that among women diagnosed before 1995, the rate of death 
from HER2 type was more than twice as high (age-adjusted HR 2.3, 95% CI 1.5-3.5) as for 
Luminal A. The corresponding HR for women diagnosed with HER2 type in 1995 or later 
was much higher (age-adjusted HR 5.1, 95% CI 2.8-9.3). Adjusting for histopathological 
grade or stage of disease at diagnosis did not substantially influence these results. 
We also used Cox regression analysis to compare rates of death for each subtype 
between diagnostic periods (Table 3). Generally, rates of death were lower for women 
diagnosed in 1995 or later, although precision was low for the less common subtypes. Thus, 
for the entire follow-up period, the rate of death was 60% lower for Luminal A (age-adjusted 
HR 0.4, 95% CI 0.3-0.5), 50% lower for Luminal B (HER2-) (age-adjusted HR 0.5, 95% CI 
0.3-0.7), and 60% lower for Basal phenotype (age-adjusted HR 0.4, 95% CI 0.2-0.9). Changes 
between diagnostic periods for the other subtypes were less apparent (Table 3). The results 
remained similar when analyses were restricted to the first 5 and 15 years after diagnosis, with 
clear improvements in survival between diagnostic periods for Luminal A, Luminal B 
(HER2-) and Basal phenotype (Supplementary Table 3). Analyses based on the four subtypes 
determined by ER, PR, and HER2 status showed that both before and after 1995, the ER+, 
PR+, HER2- subtype had the best prognosis (Supplementary Table 4, and Supplementary 
Figure 3). Comparing prognosis between diagnostic periods, clear improvements were seen 
for the ER+, PR+, HER2- subtype (HR 0.4 (95% CI 0.3-0.5)), and for the triple negative (ER-





This large population-based study of women born between 1886 and 1977 shows that for 
women aged 50-69 years, the incidence of breast cancer was higher among those born in 1929 
or later, compared to women born before 1929. This was primarily due to a much higher 
incidence of the low-proliferative Luminal A tumours, but also to some extent for Luminal B 
(HER2-) tumours. The prognosis was generally better for women diagnosed in 1995 or later, 
compared to before 1995, but clear improvements in prognosis were seen for Luminal A, 
Luminal B (HER2-), and the Basal phenotype. Luminal A had the best prognosis and HER2 
type had the poorest in both diagnostic periods.  
The participants came from a single county in Norway, which is predominantly rural 
and ethnically homogeneous, with little migration (14). This increases the comparability over 
time within the study population. Incident tumours were reclassified into molecular subtypes 
and included in analyses of incidence and long-term prognosis, using reliable end-point data 
from national registries. 
Molecular subtyping was performed in the same laboratory, using the same antibodies 
for IHC in all tumours. This ensured that the observed incidence differences were not caused 
by different antibody sensitivities or cut-off levels. Subtyping of tumours was done according 
to the same algorithm. Tumour tissue covered a diagnostic time span of several decades, and 
although preanalytical conditions may have varied, valuable information can be drawn from 
archival tissue blocks (29). 
Most breast cancers are hormone receptor positive (luminal) and HER2 negative. Our 
results are in agreement with previous studies showing that HER2 negative luminal tumours 
are more common among older, postmenopausal women (30, 31), and that non-luminal 
subtypes are more common in younger women (30, 31).  
15 
 
Increased incidence of breast cancer over time has been reported by others (3, 4, 32), 
and ER positive tumours may account for most of this increase (3, 32, 33).  It has been 
suggested that mammography screening favours detection of HER2 negative luminal tumours 
(34-37) and that menopausal hormone use may increase the risk for hormone receptor positive 
tumours (38-40).   
The Norwegian Breast Cancer Screening Program was implemented in Nord-
Trøndelag County in 2001. It entails biennial screening of women aged 50-69 years. Women 
in this study who were born before 1929 were not eligible for the screening program, and 
some of the higher incidence of HER2 negative luminal tumours that we found in women 
born after 1929 could be due to a combination of increased unsystematic use of 
mammography for screening purposes during the 1990s (41, 42), and later implementation of 
organized mammography screening. 
Between 1987 and 2001, use of menopausal hormone therapy increased greatly in 
Norway, after which an increase in hormone receptor positive tumours (ER and/or PR >10%) 
was observed (41). The use of hormone therapy declined after 2001 (43, 44).  
The observed increase in use of menopausal hormone therapy concurred with 
increased use of mammography for screening purposes. Therefore, some of the higher 
incidence of Luminal A and Luminal B (HER2-) tumours observed for women born between 
1929 and 1977 may be attributed to mammography screening and menopausal hormone 
therapy (3, 41, 45), both of which were negligible exposures in women born before 1929. 
The impact of risk factors seems to differ between molecular subtypes, and it is 
possible that the higher incidence of HER2 negative luminal tumours among women born in 
1929 or later may also be explained by differences in reproductive and lifestyle factors, such 
as age at menarche, age at first birth, parity, age at menopause, and body mass index (39, 40, 
46, 47).  
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Some tumours were unavailable for subtyping (34% of cases born before 1929, and 
9% of cases born in 1929 or later), mainly because patients were diagnosed at other hospitals. 
We therefore used multiple imputations to compensate for the resulting underestimation of 
subtype-specific incidence rates. Even when all clinical information available is included in 
the imputation models, it is difficult to assess how well the imputed rates reflect the true rates 
for each subtype. This uncertainty is also reflected in the relatively wide confidence intervals 
for the imputed rates. Although weaker after imputation, the differences in incidence rates 
persisted for the HER2 negative luminal subtypes, whereas the observed differences for 
Luminal B (HER+) and non-luminal subtypes disappeared after imputation for unknown 
subtype. Imputations had stronger effects on the subtype-specific rates for women born before 
1929, due to a higher frequency of unknown subtype among these women.   
Breast cancer mortality in Norway has declined since the mid-1990s, and this has been 
attributed to earlier detection (48, 49), and improved treatment (50-52). We found that the 
prognosis was generally better for women diagnosed with breast cancer in 1995 or later, 
compared to before 1995, confirming the findings of others (6, 23, 53).  
Differences in prognosis (9, 54) and treatment response (55, 56) between subtypes 
have been demonstrated, and in accordance with others, we found clear reductions in case 
fatality for HER2 negative luminal subtypes from the first to the second diagnostic period (6, 
53). We also found clear reductions in case fatality for the Basal phenotype.  
The HER2 type had the worst prognosis irrespective of diagnostic period, and 
compared to Luminal A, the relative rate of death from HER2 type increased dramatically 
from the first to the second diagnostic period. This increase could probably be attributed to 
longer survival among Luminal A patients diagnosed in 1995 or later. Since Luminal tumours 
are more likely to be detected by screening (34-36), it is plausible that the longer survival 
among many Luminal A cases diagnosed after 1995 may be due to earlier detection by 
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mammography (lead-time bias). Aggressive subtypes, such as the Basal phenotype or the 
HER2 type, are more likely to present clinically, and lead-time bias may be a negligible issue 
for these subtypes (34-37). 
Contrary to others (23), we could not demonstrate clear improvements in survival for 
the HER2 type between diagnostic periods. One possible explanation could be that targeted 
treatment with trastuzumab was not implemented until the last years of the observation 
period. 
In conclusion, there has been a dramatic secular increase in the incidence rates of 
Luminal A and Luminal B (HER2-) breast cancer, whereas the incidence of Luminal B 
(HER2+) and non-luminal subtypes have remained relatively stable. The prognoses for 
Luminal A, Luminal B (HER2-), and Basal phenotype have clearly improved after 1995.  
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Table 1. Incidence rates and incidence rate ratios of breast cancer molecular subtypes according to age at diagnosis and year of birth. Observed and 
imputed estimates. 
  Observed Imputeda 
  
Incidence rate  
(cases/100 000 person-years) 
 
Incidence rate  
(cases/100 000 person-years) 
 
Molecular subtype Age 
Women born  
1886-1928 
Women born  
1929-1977 
IRR (95% CI) 
Women born  
1886-1928 
Women born  
1929-1977 
IRR (95% CI) 
Totalb 50-54 97.3 195.7 2.1 (1.5-2.8)     
 55-59 122.6 213.2 1.7 (1.3-2.3)     
 60-64 149.5 309.4 2.1 (1.6-2.7)     
 65-69 179.7 235.5 1.3 (1.0-1.7)     
Luminal A 50-54 9.9 76.1 7.7 (3.4-17.4) 24.3 84.7 3.5 (1.8-6.9) 
 55-59 17.7 118.4 6.7 (3.8-11.9) 34.9 132.3 3.8 (2.3-6.4) 
 60-64 35.5 158.9 4.5 (2.9-6.8) 54.9 177.3 3.2 (2.2-4.8) 
 65-69 60.9 142.0 2.3 (1.6-3.5) 86.4 154.3 1.8 (1.2-2.6) 
Luminal B (HER2-) 50-54 8.5 50.0 5.9 (2.4-14.5) 23.1 57.6 2.5 (1.2-5.2) 
 55-59 25.9 37.9 1.5 (0.8-2.8) 45.3 44.7 1.0 (0.5-1.9) 
 60-64 19.9 66.9 3.4 (1.8-6.2) 37.5 71.9 1.9 (1.1-3.4) 
 65-69 32.4 38.1 1.2 (0.6-2.3) 49.5 41.6 0.8 (0.4-1.6) 
Luminal B (HER2+) 50-59 9.6 10.2 1.1 (0.5-2.4) 17.6 13.8 0.8 (0.4-1.7) 
 60-69 8.1 21.6 2.7 (1.3-5.5) 14.0 23.1 1.7 (0.8-3.5) 
HER2 type 50-59 8.3 11.3 1.4 (0.6-3.1) 18.2 13.9 0.8 (0.4-1.6) 
 60-69 9.1 7.7 0.8 (0.3-2.3) 15.1 9.4 0.6 (0.2-1.6) 
5 negative phenotype 50-59c - - - - - - - - 
 60-69 5.6 7.7 1.4 (0.5-4.0) 10.1 9.1 0.9 (0.3-2.6) 
Basal phenotype 50-59 4.5 13.6 3.0 (1.2-7.8) 8.9 16.2 1.8 (0.8-4.3) 
 60-69 7.1 7.7 1.1 (0.4-3.0) 11.1 9.0 0.8 (0.3-2.6) 
Abbreviations: IRR=Incidence rate ratio, CI=Confidence interval, HER2=Human epidermal growth factor receptor 2  
a Based on 50 imputed datasets using age (5-year categories) and calendar year at diagnosis (continuous), stage (I, II, III, IV, unknown) and extent of disease (disease localized to the breast, local 
invasion, regional lymph nodes, distant lymph nodes or organ metastases, unknown) as reported by the Cancer Registry of Norway, year of birth (5-year categories), observation time after 
diagnosis (log-transformed, continuous) and survival status (alive, death from breast cancer, death from other causes). b Total breast cancer incidence from the Cancer Registry of Norway, 
including cases with unknown subtype.c Too few observations. 
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Table 2: Characteristics of breast cancer cases with successfully subtyped 
tumours. 




1995 or later 
   Number of women 661 762 
   Mean age at diagnosis (SD) 69.5 (10.4) 65.5 (14.3) 
   Mean follow-up after diagnosis (SD) 9.8 (8.7) 7.9 (4.4) 
   Deaths from breast cancer (%) 293 (44) 131 (17) 
   Deaths from other causes (%) 316 (48) 145 (19) 
Molecular subtype (%) 
   Luminal A 291 (44) 414 (54) 
   Luminal B (HER2-) 194 (29) 183 (24) 
   Luminal B (HER2+) 55 (8) 57 (7) 
   HER2 type 53 (8) 36 (5) 
   5 negative phenotype 23 (3) 25 (3) 
   Basal phenotype 45 (7) 47 (6) 
Histopathological grade (%) 
   1 78 (12) 145 (19) 
   2 346 (52) 397 (52) 
   3 237 (36) 220 (29) 
   Unknown -  -  
Regional lymph node metastasis (%) 
   Yes 234 (35) 239 (31) 
   No  238 (35) 418 (55) 
   Unknown histopathologya 189 (29) 105 (14) 
Tumor size (%) 
   ≤2 cm 268   (41) 466 (61) 
   >2 cm-5 cm 27 (4) 236 (31) 
   >5 cm 9  (1) 29 (4) 
   Uncertain, but >2 cm 141 (21) 4 (1) 
   Uncertain 216  (33) 27 (4) 
Stage (%)b  
   I 338 (51) 390 (51) 
   II 239 (36) 314 (41) 
   III 43 (7) 35 (5) 
   IV 35 (5) 23 (3) 
   Unknown 6 (1) -  
Extent of disease (%)b  
   Disease localized to the breast 225 (34) 369 (48) 
   Local invasion 23 (3) 14  (2) 
   Regional lymph nodes 155 (23) 234 (31) 
   Distant lymph node or organ metastases 25 (4) 22 (3) 
   Unknown    233 (35) 123 (16) 
Abbreviations:  
SD=Standard deviation, HER2=Human epidermal growth factor receptor 2 
a Includes cases where histopathological examination was done, but reports were not available, and cases where 
no axillary lymph nodes were removed. 





Table 3.  Absolute and relative risk of death from breast cancer according to molecular subtype and diagnostic period. 
 
 Cumulative incidence of death from breast cancer 
Age-adjusted hazard ratio of death from 
breast cancer a 
 
 
First 5 years after 
diagnosis 
First 15 years after 
diagnosis 















HR (95% CI) 
Between periods 
HR (95% CI)b 
Women diagnosed before 1995        
   Luminal A 291 54 19 (15-24) 103 37 (32-44) 112 1.0 1 
   Luminal B (HER2-) 194 45 23 (18-30) 79 42 (35-49) 87 1.3 (1.0-1.7) 1 
   Luminal B (HER2+) 55 20 36 (25-51) 25 46 (34-60) 28 1.3 (0.9-2.0) 1 
   HER2 type 53 27 51 (38-65) 30 57 (44-71) 31 2.3 (1.5-3.5) 1 
   5 negative phenotype 23 10 43 (26-66) 13 57 (38-77) 13 1.7 (1.0-3.1) 1 
   Basal phenotype 45 18 40 (27-56) 22 50 (36-65) 22 1.6 (1.0-2.5) 1 
Women diagnosed in 1995 or later        
   Luminal A 414 30 7 (5-10) 44 13 (9-17) 44 1.0 0.4 (0.3-0.5) 
   Luminal B (HER2-) 183 25 14 (10-20) 34 23 (16-32) 34 2.0 (1.2-3.1) 0.5 (0.3-0.7) 
   Luminal B (HER2+) 57 11 20 (11-32) 18 42 (27-63) 18 3.6 (2.1-6.3) 0.7 (0.4-1.3) 
   HER2 type 36 13 36 (23-54) 15 42 (28-60) 15 5.1 (2.8-9.3) 0.6 (0.3-1.1) 
   5 negative phenotype 25 8 32 (17-54) 9 36 (21-58) 9 4.2 (2.0-8.6) 0.6 (0.3-1.6) 
   Basal phenotype 47 9 20 (11-34) 11 26 (15-42) 11 2.7 (1.4-5.2) 0.4 (0.2-0.9) 
Abbreviations: Cum. inc.=Cumulative incidence, HR=Hazard ratio, CI=Confidence interval, HER2=Human epidermal growth factor receptor 2 
aHR from Cox regression, adjusted for age (45-49, 50-59, 60-64, 65-69, 70-74, 75+ years). Adjustments for grade or stage of disease did not substantially influence the results. 

















Titles and legends to figures 
Figure 1. Overview of study population. A: Analysis of breast cancer incidence. B: Analysis of breast 
cancer prognosis. 
Figure 2. Subtype-specific breast cancer incidence rates according to age and year of birth. Blue 
lines: Women born before 1929. Red lines: Women born in 1929 or later. Dotted lines (red and blue) 
represent incidence rates of subtyped cases. Solid lines (red and blue) represent average incidence 
rates from 50 imputed datasets with corresponding 95% confidence intervals (CIs). A) Luminal A, B) 
Luminal B (HER2-), C) Luminal B (HER2+), D) HER2 type, E) 5 negative phenotype, and F) Basal 
phenotype.   
Figure 3. Cumulative incidence of death from breast cancer according to molecular subtypes. A: 
Women diagnosed before 1995 (Gray’s test: p=0.0004). B: Women diagnosed in 1995 or later (Gray’s 
test: p=<0.0001).  
 
 
Titles and legends to Supplementary Figures. 
Supplementary Figure 1. Breast cancer incidence rates according to age and year of birth. Blue lines: 
Women born before 1929. Red lines: Women born in 1929 or later. Dashed lines (red and blue) 
represent incidence rates of subtyped cases. Dotted lines (red and blue) represent incidence rates of 
cases with unknown subtype. Solid lines (red and blue) represent the total incidence rates (subtyped 
cases and cases with unknown subtype combined).   
Supplementary Figure 2. Subtype-specific incidence rates according to age and year of birth. Blue 
lines: Women born before 1929. Red lines: Women born in 1929 or later. Dotted lines (red and blue) 
represent incidence rates of subtyped cases. Solid lines (red and blue) represent average incidence 
rates from 50 imputed datasets with corresponding 95% confidence intervals (CIs).  
Supplementary Figure 3. Cumulative incidence of death from breast cancer according to breast 
cancer subtypes. A: Women diagnosed before 1995 (Gray’s test: p=0.0002). B: Women diagnosed in 
1995 or later (Gray’s test: p<0.0001).  
 
Supplementary Table 1: Characteristics of the study population used in estimations of breast cancer 
incidence 
 Cohort 1 Cohort 2a 
Women followed for breast cancer 
occurrence 
Women born  
1886-1928 
Women born   
1929-1977 
   Number of women 25 727 27 222 
   Mean age at baseline (SD) 51.0 (11.6) 43.4 (12.8) 
   Mean duration of follow-up (SD) 29.7 (13.9) 13.1 (1.7) 
   Number of incident breast cancers 1379 529 
   
Women with incident breast cancer Subtyped Not subtyped Subtyped Not subtyped 
   Number of cases 909 470 480 49 
   Mean age at diagnosis (SD) 73.0 (10.7) 67.8 (12.9) 57.3 (9.5) 56.7 (7.9) 
   Mean follow-up after diagnosis (SD) 8.8 (8.0) 9.5 (10.5) 8.9 (4.0) 8.1 (4.4) 
   Deaths from breast cancer (%) 359 (39) 242 (51) 54 (11) 9 (18) 
   Deaths from other causes (%) 413 (45) 199 (42) 38 (8) 3 (6) 
Molecular subtype (%) 
   Luminal A 433 (48) -  255 (53) -  
   Luminal B (HER2-) 248 (27) -  121 (25) -  
   Luminal B (HER2+) 71 (8) -  37 (8) -  
   HER2 type 62 (7) -  26 (5) -  
   5 negative phenotype 33 (4) -  12 (3) -  
   Basal phenotype 62 (7) -  29 (6) -  
Stage (%)b 
   I 455 (50) 216 (46) 260 (54) 32 (65) 
   II 346 (38) 137 (29) 194 (40) 11 (22) 
   III 57 (6) 36 (8) 15 (3) 1 (2) 
   IV 45 (5) 71 (15) 11 (2) 5 (10) 
   Unknown 6 (1) 10 (2) -  -  
Extent of disease (%)b  
   Disease localized to the breast 309 (34) 192 (41) 267 (56) 29 (59) 
   Local invasion 30 (3) 12 (3) 3 (1) -  
   Regional lymph nodes 229 (25) 134 (29) 155 (32) 11 (22) 
   Distant lymph node or organ metastases 35 (4) 64 (14) 10 (2) 4 (8) 
   Unknown    306 (34) 68 (14) 45 (9) 5 (10) 
Abbreviations: SD=Standard deviation, HER2=Human epidermal growth factor receptor 2 
aIn estimations of breast cancer incidence, Cohort 2 was restricted to women born after 1928 in order to avoid duplicate 
observations. 
b As recorded by the Cancer Registry of Norway. Information is based on histopathological and/or clinical examination. 
 
 
Supplementary Table 2. Incidence rates and incidence rate ratios of breast cancer according to hormone and HER2 receptor status, age at diagnosis and 
year of birth. Observed and imputed estimates. 
  Observed Imputeda 
  
Incidence rate  
(cases/100 000 person-years) 
 
Incidence rate  
(cases/100 000 person-years) 
 
Breast cancer subtype Age 
Women born  
1886-1928 
Women born  
1929-1977 
IRR 95% CI 
Women born  
1886-1928 
Women born  
1929-1977 
IRR 95% CI 
Totalb 50-54 97.3 195.7 2.1 (1.5-2.8)     
 55-59 122.6 213.2 1.7 (1.3-2.3)     
 60-64 149.5 309.4 2.1 (1.6-2.7)     
 65-69 179.7 235.5 1.3 (1.0-1.7)     
ER+ and/or PR+, HER2- 50-54 18.3 126.1 6.9 (3.8-12.6) 45.9 142.6 3.1 (1.9-5.1) 
 55-59 43.6 156.3 3.6 (2.4-5.4) 78.8 177.9 2.3 (1.6-3.2) 
 60-64 55.4 225.8 4.1 (2.9-5.8) 94.2 249.8 2.7 (2.0-3.6) 
 65-69 93.3 180.1 1.9 (1.4-2.7) 135.9 196.4 1.4 (1.1-2.0) 
ER+ and/or PR+, HER2+ 50-59 9.6 10.2 1.1 (0.5-2.4) 17.9 13.6 0.8 (0.3-1.7) 
 60-69 8.1 21.6 2.7 (1.3-5.5) 13.9 23.8 1.7 (0.8-3.5) 
ER- and PR-, HER2+ 50-59 8.3 11.3 1.4 (0.6-3.1) 18.3 13.4 0.7 (0.3-1.6) 
 60-69 9.1 7.7 0.8 (0.3-2.3) 15.3 9.0 0.6 (0.2-1.5) 
ER- and PR-, HER2- 50-59 4.5 14.7 3.3 (1.3-8.2) 10.2 17.2 1.7 (0.7-4.0) 
 60-69 12.7 15.4 1.2 (0.6-2.5) 19.7 17.4 0.9 (0.4-1.8) 
Abbreviations: IRR=Incidence rate ratio, CI=Confidence interval, HER2=Human epidermal growth factor receptor 2  
a Based on 50 imputed datasets using age (5-year categories) and calendar year at diagnosis (continuous), stage (I, II, III, IV, unknown) and extent of extent of disease (disease localized to the 
breast, local invasion, regional lymph nodes, distant lymph nodes or organ metastases, unknown) as reported by the Cancer Registry of Norway, year of birth (5-year categories), observation 
time after diagnosis (log-transformed, continuous) and survival status (alive at end of follow-up, death from breast cancer, death from other causes). 
b Total breast cancer incidence from the Cancer Registry of Norway, including cases with unknown subtype.  
 
Supplementary Table 3. Risk of death from breast cancer between diagnostic periods, for each 




1995 or later vs. before 1995a 
First 5 years after diagnosis First 15 years after diagnosis 
HRb 95% CI HRb 95% CI 
   Luminal A 0.4 0.3-0.7 0.4 0.3-0.5 
   Luminal B (HER2-) 0.6 0.3-0.9 0.5 0.3-0.7 
   Luminal B (HER2+) 0.5 0.2-1.0 0.7 0.4-1.4 
   HER2 type 0.6 0.3-1.1 0.6 0.3-1.1 
   5 negative phenotype 0.9 0.3-2.4 0.6 0.3-1.6 
   Basal phenotype 0.4 0.2-0.8 0.4 0.2-0.9 
Abbreviations: HR=Hazard ratio, CI=Confidence interval, HER2=Human epidermal growth factor 
receptor 2 
aDiagnosis before 1995 was used as the reference.  
bHR from Cox regression, adjusted for age (≤49, 50-59, 60-64, 65-69, 70-74, 75+ years). Adjustments for grade or stage 






Supplementary Table 4. Absolute and relative risk of death from breast cancer according to breast cancer subtype and diagnostic period. 
  
Cumulative incidence of death from breast cancer 
Age-adjusted hazard ratio of death from breast 
cancer a 
 First 5 years after 
diagnosis 
First 15 years after 
diagnosis 
















HR (95% CI) 
Between periods 
HR (95% CI)b 
Women diagnosed before 1995 
   ER+ and/or PR+, HER2- 485 99 20 (17-24) 182 39 (35-44) 199 1.0 1 
   ER+ and/or PR+, HER2+ 55 20 36 (25-51) 25 46 (34-60) 28 1.2 (0.8-1.8) 1 
   ER- and PR-, HER2+ 53 27 51 (38-65) 30 57 (44-71) 31 2.1 (1.4-3.0) 1 
   ER- and PR-, HER2- 68 28 41 (31-54) 35 52 (41-65) 35 1.4 (1.0-2.1) 1 
Women diagnosed in 1995 or later 
   ER+ and/or PR+, HER2- 597 55 9 (7-12) 78 16 (13-20) 78 1.0 0.4 (0.3-0.5) 
   ER+ and/or PR+, HER2+ 57 11 20 (11-32) 18 42 (27-63) 18 2.8 (1.7-4.7) 0.7 (0.4-1.3) 
   ER- and PR-, HER2+ 36 13 36 (23-54) 15 42 (28-60) 15 4.0 (2.3-7.0) 0.6 (0.3-1.1) 
   ER- and PR-, HER2- 72 17 24 (16-37) 20 29 (20-42) 20 2.5 (1.5-4.1) 0.5 (0.3-0.9) 
Abbreviations: Cum. inc.= Cumulative incidence, HR=Hazard ratio, CI=Confidence interval, HER2=Human epidermal growth factor receptor 2 
aHR from Cox regression, adjusted for age (≤49, 50-59, 60-64, 65-69, 70-74, 75+ years). Adjustments for grade or stage of disease did not substantially influence the results.  
bDiagnosis before 1995 was used as the reference.  
Supplementary Table 5. Risk of death from breast cancer between diagnostic periods, for each 
breast cancer subtype 5 and 15 years after diagnosis (Cox regression analysis). 
 
 
Breast cancer subtype 
1995 or later vs. before 1995a 
First 5 years after diagnosis First 15 years after diagnosis 
HRb 95% CI HRb 95% CI 
   ER+ and/or PR+, HER2- 0.4 0.3-0.6 0.4 0.3-0.5 
   ER+ and/or PR+, HER2+ 0.5 0.2-1.0 0.7 0.4-1.4 
   ER- and PR-, HER2+ 0.6 0.3-1.1 0.6 0.3-1.1 
   ER- and PR-, HER2- 0.5 0.3-1.0 0.5 0.3-0.9 
Abbreviations: HR=Hazard ratio, CI=Confidence interval, HER2=Human epidermal growth factor 
receptor 2 
aDiagnosis before 1995 was used as the reference.  
bHR from Cox regression, adjusted for age (≤49, 50-59, 60-64, 65-69, 70-74, 75+ years). Adjustments for grade or stage 
of disease did not substantially influence the results. 
 
